Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, today reported that nearly 100 Nociscan procedures have been performed at The London Clinic, one of the United Kingdom's leading private hospitals. The company also released a new video featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic and Lead Clinician at The London Spine Clinic, discussing his experience with the technology.
Nociscan is a non-invasive diagnostic platform that uses MR spectroscopy and proprietary signal processing to identify chemical biomarkers associated with disc pain, helping physicians differentiate between painful and non-painful discs in the lumbar spine. According to Aclarion, the continued use of Nociscan at The London Clinic reflects sustained physician engagement and growing integration into routine clinical practice.
Mr. Sutcliffe, who has more than 30 years of experience treating spinal conditions, noted in the video that Nociscan provides an additional layer of insight that complements traditional imaging. "Having more objective data can help inform clinical decisions and improve confidence when evaluating patients with chronic low back pain," he said.
The video is available here. Aclarion's CEO Brent Ness commented, "Approaching 100 scans at a leading international center like The London Clinic is an important indicator of increasing adoption and reinforces the potential for Nociscan to become a valuable tool in the evaluation of chronic low back pain."
Chronic low back pain affects approximately 266 million people globally. Clinical data has shown up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. Aclarion's technology leverages Magnetic Resonance Spectroscopy, biomarkers, and augmented intelligence algorithms to optimize clinical treatments.
For more information on Nociscan, visit www.aclarion.com. To find a Nociscan center, view the site map here.
